Cancer Associated Thrombosis:how many lung cancer patients seen in clinical practice would be eligible to a DOAC randomized controlled trial?
B. Petit (Saint Etienne, France), V. Mismetti (Saint Etienne, France), S. Soudet (Amiens, France), G. Poenou (Paris, France), E. Zarrat (Amiens, France), T. Machuron (Saint-Etienne, France), S. Acassat (Saint-Etienne, France), L. Plaisance (Paris, France), H. Helfer (Paris, France), C. Le Hello (Saint-Etienne, France), M. Sevestre (Amiens, France), I. Mahé (Paris, France), L. Bertoletti (Saint-Etienne, France)
Source: International Congress 2022 – Pulmonary embolism: acute and long-term management
Session: Pulmonary embolism: acute and long-term management
Session type: Oral Presentation
Number: 3130
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Petit (Saint Etienne, France), V. Mismetti (Saint Etienne, France), S. Soudet (Amiens, France), G. Poenou (Paris, France), E. Zarrat (Amiens, France), T. Machuron (Saint-Etienne, France), S. Acassat (Saint-Etienne, France), L. Plaisance (Paris, France), H. Helfer (Paris, France), C. Le Hello (Saint-Etienne, France), M. Sevestre (Amiens, France), I. Mahé (Paris, France), L. Bertoletti (Saint-Etienne, France). Cancer Associated Thrombosis:how many lung cancer patients seen in clinical practice would be eligible to a DOAC randomized controlled trial?. 3130
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|